Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
admin 24th October 2017 Uncategorised 0Defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer medications Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year into ranges that many Big Pharma peers have pledged to avoid.
More: Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
Source: fierce